Ron Bentsur Purchases 5,000 Shares of Nuvectis Pharma (NASDAQ:NVCT) Stock

Nuvectis Pharma, Inc. (NASDAQ:NVCT) CEO Ron Bentsur bought 5,000 shares of Nuvectis Pharma stock in a transaction dated Wednesday, November 5th. The stock was purchased at an average price of $5.72 per share, with a total value of $28,600.00. Following the purchase, the chief executive officer directly owned 3,525,924 shares in the company, valued at approximately $20,168,285.28. This trade represents a 0.14% increase in their position. The purchase was disclosed in a legal filing with the SEC, which is available through this link.

Nuvectis Pharma Stock Up 8.3%

Shares of Nuvectis Pharma stock opened at $6.14 on Friday. The firm has a market cap of $157.28 million, a price-to-earnings ratio of -4.48 and a beta of -0.28. Nuvectis Pharma, Inc. has a 52-week low of $4.44 and a 52-week high of $11.80. The company’s 50-day simple moving average is $6.20 and its 200-day simple moving average is $7.52.

Nuvectis Pharma (NASDAQ:NVCT) last announced its quarterly earnings data on Tuesday, November 4th. The company reported ($0.44) EPS for the quarter, missing analysts’ consensus estimates of ($0.24) by ($0.20). Equities research analysts anticipate that Nuvectis Pharma, Inc. will post -1.01 EPS for the current year.

Analyst Ratings Changes

NVCT has been the topic of a number of analyst reports. Weiss Ratings restated a “sell (e+)” rating on shares of Nuvectis Pharma in a research note on Wednesday, October 8th. HC Wainwright reduced their target price on Nuvectis Pharma from $15.00 to $10.00 and set a “buy” rating for the company in a report on Monday, August 4th. Three research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $15.33.

Institutional Investors Weigh In On Nuvectis Pharma

A number of institutional investors and hedge funds have recently modified their holdings of NVCT. Iridian Asset Management LLC CT acquired a new position in Nuvectis Pharma during the first quarter worth $2,481,000. Geode Capital Management LLC grew its holdings in Nuvectis Pharma by 110.8% in the second quarter. Geode Capital Management LLC now owns 285,332 shares of the company’s stock valued at $2,132,000 after purchasing an additional 149,999 shares during the last quarter. Goldman Sachs Group Inc. purchased a new position in shares of Nuvectis Pharma in the first quarter valued at $446,000. Jane Street Group LLC acquired a new position in shares of Nuvectis Pharma during the 1st quarter worth $413,000. Finally, Austin Wealth Management LLC purchased a new stake in shares of Nuvectis Pharma in the 1st quarter worth about $393,000. Institutional investors and hedge funds own 96.77% of the company’s stock.

About Nuvectis Pharma

Nuvectis Pharma, Inc, a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. The company's lead product candidate is NXP800, a novel small molecule that is in Phase 1b clinical trials for the treatment of patients with platinum-resistant, ARID1a-mutated ovarian carcinoma.